

28 April 2021

# Allied Minds

## OcuTerra Therapeutics Raises Series B Financing

Allied Minds plc (LSE: ALM), the IP commercialisation company focused on early stage company development within the technology sector, announces that its portfolio company, OcuTerra Therapeutics, Inc. has closed a Series B funding round for approximately \$14.6 million. Proceeds from the round will be used to prepare for, conduct and report on the results of a future Phase II clinical trial of its OTT166 asset, among other working capital needs. As previously disclosed, OcuTerra has been seeking to raise external equity financing since 2018. It remains uncertain if OcuTerra will be successful in securing further all of the required funds that may be needed to continue developing its OTT166 asset.

The transaction was completed at a pre-money valuation of \$16.0 million. Allied Minds' existing shares of Special Convertible Stock (purchased at an aggregate purchase price of \$2.0 million) automatically converted into shares of Series B Preferred Stock. Following the first closing, Allied Minds' ownership of issued share capital is 28.5% and fully-diluted ownership is 21.9%.

For more information, please contact:

**Allied Minds plc**  
Harry Rein

c/o Instinctif Partners

**Instinctif**  
Tim Linacre, Rozi Morris, Hannah  
Campbell

[alliedminds@instinctif.com](mailto:alliedminds@instinctif.com)

### **About Allied Minds**

Allied Minds plc is an IP commercialisation company focused on early stage company development within the technology sector. With origination relationships that span US federal laboratories, universities, and leading US corporations, Allied Minds historically created, and now operates and funds, a portfolio of companies to generate long-term value for its investors and stakeholders. Based in Boston, Allied Minds supports its businesses with capital, management, expertise and shared services. For more information, please visit [www.alliedminds.com](http://www.alliedminds.com).

### **About OcuTerra Therapeutics**

OcuTerra Therapeutics, Inc., formerly known as SciFluor Life Sciences, Inc., is an ophthalmology drug development company, based in Boston, MA, USA, focused on treating eye diseases with innovative new products. The Company is advancing OTT166 into mid-stage clinical development for the treatment of diabetic retinopathy, a disease affecting the back of the eye that is becoming increasingly prevalent with the global epidemic of diabetes. OTT166 is designed to be administered as an eye drop by the patient at home and thus has the potential to dramatically change the treatment paradigm, eliminating the need for repeated in-office intravitreal injections.

### **Allied Minds Forward-Looking Statement**

This press release contains statements that are or may be forward-looking statements, including statements that relate to Allied Minds' future prospects, developments and strategies. The forward-looking statements are based on current expectations and are

subject to known and unknown risks and uncertainties that could cause actual results, performance and achievements to differ materially from current expectations, including, but not limited to, those risks and uncertainties described in the risk factors included in Allied Minds' regulatory filings. These forward-looking statements are based on assumptions regarding the present and future business strategies of Allied Minds and the environment in which it will operate in the future. Each forward-looking statement speaks only as at the date of this press release. Except as required by law, regulatory requirement, the Listing Rules and the Disclosure Guidance and Transparency Rules, neither Allied Minds nor any other party intends to update or revise these forward-looking statements, whether as a result of new information, future events or otherwise.

###

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [rns@lse.com](mailto:rns@lse.com) or visit [www.rns.com](http://www.rns.com).

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

MSCEAALXADAFEAA